Intra-Cellular Ther (ITCI) 37.74 $ITCI
Intra-Cellular Therapies to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS"
disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies 2016 Healthcare Conference in New York. The presentation is scheduled for Tuesday, June 7, 2016 at 2:30 p.m. EDT.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the American Society of Clinical Psychopharmacology 2016 Annual Meeting
GlobeNewswire - Thu May 26, 7:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company's lead product candidate, will be featured in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting, to be held May 30 - June 3 in Scottsdale, Arizona at the Fairmont Scottsdale Princess Hotel.
ITCI: 37.74 (+1.83)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 24.41 (+0.57), ANTH: 2.75 (-0.35), VTAE: 10.54 (+0.15), ITCI: 37.74 (+1.83)
Intra-Cellular Therapies presents at the Annual Meetings of the Society of Biological Psychiatry and the American Psychiatric Association
GlobeNewswire - Wed May 18, 6:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it presented posters related to ITI-007, the Company's lead product candidate, at the 2016 Society of Biological Psychiatry (SOBP) Annual Meeting and the 2016 American Psychiatric Association (APA) Annual Meeting.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the American Psychiatric Association 169th Annual Meeting and the Society of Biological Psychiatry 71st Annual Meeting
GlobeNewswire - Tue May 10, 7:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company's lead product candidate, will be featured in several poster presentations at the following meetings:
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Wed May 04, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS" disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 11, 2016 at 9:20 a.m. PDT.
ITCI: 37.74 (+1.83)
Intra-Cellular reports 1Q loss
Automated Insights - Thu Apr 28, 8:32AM CDT
NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $27.8 million in its first quarter.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Apr 28, 6:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the quarter ended March 31, 2016, and provided a corporate update.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Host First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, April 28, 2016, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March, 31, 2016.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies Presents Additional ITI-007 Data at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it delivered an oral presentation and presented several posters featuring data on ITI-007, the Company's lead drug candidate at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference being held in Florence, Italy.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 04, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS" disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 15 Annual Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 12, 2016 at 4:20 p.m. EDT.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies Announces Upcoming Presentations at the 5th Biennial Schizophrenia International Research Society Conference
GlobeNewswire - Wed Mar 30, 3:30PM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and three posters on ITI-007, the Company's lead drug candidate, will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference. The meeting will be held April 2-6, 2016, in Florence, Italy.
ITCI: 37.74 (+1.83)
Why Adamas Pharmaceuticals Dropped 25.3% in February
Brian Feroldi, The Motley Fool - Motley Fool - Mon Mar 07, 3:59PM CST
Image by TBIT via pixabay What: Investors in Adamas Pharmaceuticals , a small cap drug maker focused on treatments for diseases of the central nervous system, had a February to forget as the company's stock lost 25.3% of its value during the...
ADMS: 16.24 (-0.15), ITCI: 37.74 (+1.83)
Forget Gilead Sciences: These Stocks Doubled Last Year
Brian Feroldi, The Motley Fool - Motley Fool - Wed Feb 03, 1:44PM CST
Image source: Gilead Sciences. Gilead Sciences has been a dream stock for long-term investors. The stock has gained more than 4,930% since the turn of the millennium, turning the company into a $130 billion biotech behemoth. However, investors...
GILD: 81.77 (-1.60), ITCI: 37.74 (+1.83), PRTA: 40.55 (+2.38), EXEL: 7.27 (-0.58)
Global Insomnia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/65tkn8/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Insomnia Overview - Therapeutics Development - Pipeline Products for Insomnia - Overview - Pipeline Products for Insomnia - Comparative Analysis - Insomnia - Therapeutics under Development by Companies - Insomnia - Therapeutics under Investigation by Universities/Institutes - Insomnia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Insomnia - Products under Development by Companies - Insomnia - Products under Investigation by Universities/Institutes - Insomnia - Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evotec AG - Grupo Ferrer Internacional, S.A. - Heptares Therapeutics Limited - Intec Pharma ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Merck & Co., Inc. - Neurim Pharmaceuticals Ltd - Novartis AG - Reviva Pharmaceuticals Inc. - Rottapharm SpA - Shionogi & Co., Ltd. - Somnus Therapeutics, Inc. - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/65tkn8/insomnia
JNJ: 115.00 (-2.38), NTEC: 4.62 (+0.05), MRK: 56.09 (-1.59), ITCI: 37.74 (+1.83), NVS: 77.65 (-3.02)
Intra-Cellular Therapies to Present at the Leerink Partners' 5th Annual Global Healthcare Conference
GlobeNewswire - Mon Feb 01, 7:00AM CST
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS" disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Leerink Partners' 5th Annual Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, February 10th, 2016 at 8:50 am EST.
ITCI: 37.74 (+1.83)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 115.00 (-2.38), NBIX: 44.59 (+1.86), KMPH: 4.00 (-0.40), ZGNX: 8.41 (+0.11), PFE: 33.97 (-0.62), AZN: 27.58 (-1.71), TEVA: 50.00 (-1.37), ITCI: 37.74 (+1.83), OMER: 10.98 (+0.12)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.00 (-0.40), MDGN: 5.73 (+0.23), ADHD: 5.50 (+1.40), SUPN: 19.12 (+0.24), COLL: 13.70 (+0.41), DRRX: 1.24 (+0.05), NEOS: 9.65 (+0.24), NDRM: 16.84 (-0.36), MRK: 56.09 (-1.59), SHPG: 169.20 (-11.09), ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS"
disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies 2016 Healthcare Conference in New York. The presentation is scheduled for Tuesday, June 7, 2016 at 2:30 p.m. EDT. ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the American Society of Clinical Psychopharmacology 2016 Annual Meeting
GlobeNewswire - Thu May 26, 7:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company's lead product candidate, will be featured in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting, to be held May 30 - June 3 in Scottsdale, Arizona at the Fairmont Scottsdale Princess Hotel.
ITCI: 37.74 (+1.83)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 24.41 (+0.57), ANTH: 2.75 (-0.35), VTAE: 10.54 (+0.15), ITCI: 37.74 (+1.83)
Intra-Cellular Therapies presents at the Annual Meetings of the Society of Biological Psychiatry and the American Psychiatric Association
GlobeNewswire - Wed May 18, 6:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it presented posters related to ITI-007, the Company's lead product candidate, at the 2016 Society of Biological Psychiatry (SOBP) Annual Meeting and the 2016 American Psychiatric Association (APA) Annual Meeting.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the American Psychiatric Association 169th Annual Meeting and the Society of Biological Psychiatry 71st Annual Meeting
GlobeNewswire - Tue May 10, 7:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company's lead product candidate, will be featured in several poster presentations at the following meetings:
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Wed May 04, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS"
disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 11, 2016 at 9:20 a.m. PDT. ITCI: 37.74 (+1.83)
Intra-Cellular reports 1Q loss
Automated Insights - Thu Apr 28, 8:32AM CDT
NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $27.8 million in its first quarter.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Apr 28, 6:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the quarter ended March 31, 2016, and provided a corporate update.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Host First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, April 28, 2016, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March, 31, 2016.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies Presents Additional ITI-007 Data at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it delivered an oral presentation and presented several posters featuring data on ITI-007, the Company's lead drug candidate at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference being held in Florence, Italy.
ITCI: 37.74 (+1.83)
Intra-Cellular Therapies to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 04, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS"
disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 15 Annual Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 12, 2016 at 4:20 p.m. EDT. ITCI: 37.74 (+1.83)
Intra-Cellular Therapies Announces Upcoming Presentations at the 5th Biennial Schizophrenia International Research Society Conference
GlobeNewswire - Wed Mar 30, 3:30PM CDT
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and three posters on ITI-007, the Company's lead drug candidate, will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference. The meeting will be held April 2-6, 2016, in Florence, Italy.
ITCI: 37.74 (+1.83)
Why Adamas Pharmaceuticals Dropped 25.3% in February
Brian Feroldi, The Motley Fool - Motley Fool - Mon Mar 07, 3:59PM CST
Image by TBIT via pixabay What: Investors in Adamas Pharmaceuticals , a small cap drug maker focused on treatments for diseases of the central nervous system, had a February to forget as the company's stock lost 25.3% of its value during the...
ADMS: 16.24 (-0.15), ITCI: 37.74 (+1.83)
Forget Gilead Sciences: These Stocks Doubled Last Year
Brian Feroldi, The Motley Fool - Motley Fool - Wed Feb 03, 1:44PM CST
Image source: Gilead Sciences. Gilead Sciences has been a dream stock for long-term investors. The stock has gained more than 4,930% since the turn of the millennium, turning the company into a $130 billion biotech behemoth. However, investors...
GILD: 81.77 (-1.60), ITCI: 37.74 (+1.83), PRTA: 40.55 (+2.38), EXEL: 7.27 (-0.58)
Global Insomnia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/65tkn8/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Insomnia Overview - Therapeutics Development - Pipeline Products for Insomnia - Overview - Pipeline Products for Insomnia - Comparative Analysis - Insomnia - Therapeutics under Development by Companies - Insomnia - Therapeutics under Investigation by Universities/Institutes - Insomnia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Insomnia - Products under Development by Companies - Insomnia - Products under Investigation by Universities/Institutes - Insomnia - Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evotec AG - Grupo Ferrer Internacional, S.A. - Heptares Therapeutics Limited - Intec Pharma ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Merck & Co., Inc. - Neurim Pharmaceuticals Ltd - Novartis AG - Reviva Pharmaceuticals Inc. - Rottapharm SpA - Shionogi & Co., Ltd. - Somnus Therapeutics, Inc. - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/65tkn8/insomnia
JNJ: 115.00 (-2.38), NTEC: 4.62 (+0.05), MRK: 56.09 (-1.59), ITCI: 37.74 (+1.83), NVS: 77.65 (-3.02)
Intra-Cellular Therapies to Present at the Leerink Partners' 5th Annual Global Healthcare Conference
GlobeNewswire - Mon Feb 01, 7:00AM CST
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS"
disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Leerink Partners' 5th Annual Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, February 10th, 2016 at 8:50 am EST. ITCI: 37.74 (+1.83)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 115.00 (-2.38), NBIX: 44.59 (+1.86), KMPH: 4.00 (-0.40), ZGNX: 8.41 (+0.11), PFE: 33.97 (-0.62), AZN: 27.58 (-1.71), TEVA: 50.00 (-1.37), ITCI: 37.74 (+1.83), OMER: 10.98 (+0.12)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.00 (-0.40), MDGN: 5.73 (+0.23), ADHD: 5.50 (+1.40), SUPN: 19.12 (+0.24), COLL: 13.70 (+0.41), DRRX: 1.24 (+0.05), NEOS: 9.65 (+0.24), NDRM: 16.84 (-0.36), MRK: 56.09 (-1.59), SHPG: 169.20 (-11.09), ITCI: 37.74 (+1.83)
